Hilversum

• An open study for participants who have been on darolutamide treatment in any other Bayer study Ended recruitment
  2022-502084-38-00 5 2020-10-16 Cancer
• Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency (CAP … Ended recruitment
  2023-504998-20-00 5 2020-09-18 Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN def
• Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteremia (SAFE-trial) Ended recruitment
  2024-515398-90-01 5 2020-08-17 Staphylococcus aureus bacteremia
• Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX) Ended recruitment
  2023-509287-26-00 4 2019-07-01 previously untreated metastatic or locally advanced esophagogastric ca
• DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Ended recruitment
  2024-513867-19-00 5 2019-01-31 metastatic Castration-Resistant Prostate Cancer (mCRPC)
• HOVON 151 DLBCL: A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diff … Ended recruitment
  2022-501076-26-00 4 2018-08-28 high risk diffuse large B-cell lymphoma
• Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended recruitment
  2024-516204-42-00 5 2017-11-21 Breast cancer
• An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Ended recruitment
  2023-508606-26-00 5 2015-04-23 Metastatic castration-resistant prostate cancer (mCRPC)
• Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-lin … Ended recruitment
  2024-516202-39-00 4 2013-10-10 Metastatic breast cancer
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on … Ended
  2023-509569-19-00 10 2022-08-10 venous thromboembolism (VTE)
• Investigation to assess the effects of zalunfiban in patients with an acute heart attack Ended
  2023-508485-15-00 5 2021-04-22 Subjects with documented STEMI, presenting with persistent ischemic ch
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended
  2022-500413-11-00 5 2019-06-17 Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC)
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• GIVE trial (Gazyvaro In combination with VEnetoclax in Elderly CLL) Ended
  2024-511048-22-00 4 2016-10-27 Chronic lymphocytic leukemia
• A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can … Ended
  2024-517856-36-00 5 2015-03-09 Completely resected primary stage IB (≥ 4cm), II and IIIA non-small ce
• Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN) Ended
  2024-516581-11-00 5 Advanced stage NSCLC
• Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine Ended
  2024-518047-37-01 6 Depression

Showing 49–67 of 67 trials